secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001213900-26-036519
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD reports 2025 full-year net loss of $0.7M, license revenue up 71.6% to $3.0M
--------------------------------------------------------------------------------

- Net loss from continuing operations narrowed to $0.7M ($0.06 per share) from $2.3M in 2024.
- License revenue rose 71.6% to $3.0M, primarily driven by the Mayne License Agreement.
- Total operating expenses decreased 5.9% to $7.4M, partly due to lower impairment charges.
- Cash and cash equivalents stood at $7.5M as of December 31, 2025.
- Company continues to evaluate strategic alternatives including M&A or sale of assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/0001213900-26-036519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/ea0283239-8k_therapeu.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-036519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer